T-cell lymphoma

February 27, 2020February 27, 2020

Corvus’ CPI-818 Shows Promising Early Results in T-cell Lymphomas, Data Finds

News

Twice-daily treatment with Corvus Pharmaceuticals‘ potential therapy for T-cell lymphomas, CPI-818, is showing promising safety and tolerability, and preliminary signs of efficacy, according to Phase 1/1b results. The early clinical ... Read more

October 10, 2019

Copiktra Receives FDA’s Orphan Drug Status for T-cell Lymphoma Treatment

News

The small molecule inhibitor Copiktra (duvelisib) has been given orphan status by the U.S. Food and Drug Administration (FDA) for the treatment of T-cell lymphoma, the therapy’s developer, Verastem Oncology, ... Read more

February 7, 2019February 14, 2019

Stand Up To Cancer’s ‘Dream Team’ of Experts Working on New Therapies for T-cell Lymphoma

News

Stand Up To Cancer (SU2C) has put together an $8 million “dream team” of expert scientists who will focus on discovering new treatments for T-cell lymphoma based on CAR T-cell immunotherapy. ... Read more

August 22, 2018

FDA Grants CPI-613 Orphan Drug Status For Peripheral T-Cell Lymphoma Treatment

News

Therapeutic candidate CPI-613, developed by Rafael Pharmaceuticals, received orphan drug designation by the U.S. Food and Drug Administration for the treatment of peripheral T-cell lymphoma (PTCL). This is the fifth ... Read more

April 27, 2018April 27, 2018

FDA Orders Enrollment Hold on Tazemetostat Clinical Trials

News

Patient enrollment for clinical trials of Epizyme’s tazemetostat is temporarily on hold. The decision from the U.S. Food and Drug Administration (FDA) follows a safety report of a pediatric patient ... Read more

June 29, 2017

What Are the Different Types of Lymphoma in Young People?

Lymphoma is the most common form of cancer in teenagers and young adults. There are two main types of lymphoma that affect people between the ages of 15 and 24: Hodgkin’s lymphoma ... Read more

February 16, 2017

Lymphoma Patients Respond to Pembrolizumab After Other Therapies Fail, Small Study Indicates

News

Patients with NK-cell or T-cell lymphomas whose previous treatments failed showed remarkably good responses to the immunotherapy Keytruda (pembrolizumab) in a small trial. The study, “PD1 blockade with pembrolizumab is ... Read more

October 7, 2016October 7, 2016

First B-Cell Lymphoma Patients Dosed in Phase 1 Study of Potential Therapy

News

Dosing of patients has begun in a Phase 1 clinical trial evaluating the safety and tolerability of Karus Therapeutics‘ lead anti-cancer candidate, KA2237, as a treatment for B-cell lymphoma, the company announced. The ... Read more

June 16, 2016August 23, 2016

Phase 2 Study of Plitidepsin, a Potential Treatment for Rare T-cell Lymphoma, Begins

News

PharmaMar announced the start of a multicenter and prospective Phase 2 clinical trial to evaluate the efficacy of plitidepsin, a potential treatment option for adult patients with relapsed and refractory angioimmunoblastic T-cell lymphoma (AITL). Plitidepsin ... Read more